MetaVia Inc.
MTVA
Ранг среди акций
#32861
Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a... Headquartered in Cambridge, Massachusetts, MetaVia Inc. operates as a clinical-stage biotechnology company with a core focus on discovering and commercializing novel pharmaceutical solutions for cardiometabolic disorders. Its leading investigational drug, DA-1241, a unique G-Protein-Coupled Receptor 119 agonist, is currently undergoing Phase 2a clinical trials for metabolic dysfunction-associated steatohepatitis (MASH). This follows the successful completion of Phase 1 trials for type 2 diabetes mellitus (T2DM), and the compound holds promise for use as both a standalone therapy and in combination treatments. Another significant asset, DA-1726, an innovative oxyntomodulin analogue that functions as a dual agonist for GLP-1 and glucagon receptors, is presently in preclinical development specifically for treating obesity. MetaVia's broader therapeutic pipeline also includes ANA001, a distinct oral niclosamide formulation intended for moderate COVID-19 patients; NB-01, designed to address painful diabetic neuropathy; NB-02, targeting cognitive impairment; and Gemcabene, for the management of dyslipidemia. The company engages in strategic partnerships, notably a licensing agreement with Pfizer Inc. for the research, development, manufacturing, and commercialization of Gemcabene. Additionally, a joint research collaboration with Dong-A ST and ImmunoForge supports the advancement of DA-1726. The entity adopted its current name, MetaVia Inc., in November 2024, transitioning from its former identity as NeuroBo Pharmaceuticals, Inc.
Цена акции
$1.30
Последняя синхронизация: 2026-10-16
Рыночная капитализация
$8.53M
Изменение (1 день)
-5.47%
Изменение (1 год)
-20.55%
Страна
US
Торговля MetaVia Inc. (MTVA)
Категория
Healthcare
Рыночная капитализация MetaVia Inc.(MTVA)
Рыночная капитализация: $8.53M
По состоянию на October 2026 рыночная капитализация MetaVia Inc. составляет $8.53M. Согласно нашим данным, MetaVia Inc. занимает 32861st место среди самых ценных компаний мира по рыночной капитализации. Рыночная капитализация — это общая рыночная стоимость всех находящихся в обращении акций публичной компании и обычно используется для оценки ее стоимости.
История рыночной капитализации MetaVia Inc. с 2016 по 2026
MTVA по сравнению с пятеркой самых популярных stocks
